Patient Reported Outcomes and Toxicity in a Phase I/II Trial of Prostate SBRT with a Simultaneous Integrated Boost to MRI-identified Tumor (NCT02470897)

Abstract

subgroups (HR 1.7, 95% CI 1.0-2.8, p Z 0.033). In high-risk subgroups, 5year BCR-free survival rates of patients with PSA level < 0.50 and 0.50 ng/ml at BCR were 45% (95% CI, 34e55) and 28% (95% CI, 14e44), respectively (p Z 0.033). Early SRT did not improve outcomes significantly in low-and intermediate-risk groups (p Z 0.92 and 0.85, respectively). Conclusion: This study suggested that early SRT is beneficial only for selected high-risk subgroups of patients affected by BCR after RP.